Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Worldwide Pregnancy Safety Study To Assess Maternal, Fetal, And Infant Outcomes Following Exposure To Efgartigimod During Pregnancy And/Or Breastfeeding

NCT06299748 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT06299748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06299748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Worldwide Pregnancy Safety Study To Assess Maternal, Fetal, And Infant Outcomes Following Exposure To Efgartigimod During Pregnancy And/Or Breastfeeding
Lead sponsor
argenx
Phase
Observational
Overall status
Recruiting
Start date
November 30, 2023
Completion date
December 31, 2033
Enrollment
279 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cidp - chronic inflammatory demyelinating polyneuropathy, myasthenia gravis